A Successful Global Trial Paves the Way for the US FDA Approval of the First-in-Class Gonorrhoea Antibiotic

A major milestone in global health has been achieved with the U.S. FDA approval of NUZOLVENCE® (zoliflodacin), the first new antibiotic developed exclusively for the treatment of gonorrhoea in decades.